View Exam | PowerPak

1. PARP inhibitors have demonstrated considerable activity in ovarian cancer because of mutations in which of the following genes?

A. p53 B. BRAF C. KRAS D. BRCA 1/2 E. Unsure

2. A 54-year-old woman with recurrent, BRCA-positive, platinum-sensitive ovarian cancer has recently completed six cycles of paclitaxel/carboplatin with a clinical complete response. Which of the following treatment options would be reasonable for the next phase of her treatment?

A. Olaparib or bevacizumab maintenance treatment B. Rucaparib or bevacizumab maintenance treatment C. Niraparib or bevacizumab maintenance treatment D. PARP inhibitor (any) or bevacizumab maintenance treatment E. Unsure

3. Which of the following is recommended to be monitored while patients are receiving PARP-inhibitor therapy?

A. Electrocardiogram (EKG) at baseline and repeat monthly for the first 3 months of treatment B. Weekly complete blood count (CBC) and comprehensive metabolic panel (CMP) for the first 6 to 8 weeks of treatment C. Urine analysis (UA) at baseline and repeat every monthly while on treatment D. Thyroid function at baseline and repeat monthly for the first 3 months of treatment E. Unsure

4. After completing 9 cycles of liposomal doxorubicin/carboplatin, a 46-year-old patient with BRCA-negative, platinum-sensitive ovarian cancer presents to clinic with chronic renal insufficiency and wants to know about “those PARP inhibitors.” On the basis of Food and Drug Administration (FDA)-approved indications, which of the following PARP agents would you consider?

A. Rucaparib B. Niraparib C. Olaparib D. Any of the FDA-approved PARP inhibitors would be appropriate E. Unsure

5. For which diagnosis would it be appropriate to consider continuation of PARP inhibitor therapy for a patient admitted through the emergency room on a Friday evening?

A. Dehydration B. Suspected small bowel obstruction C. Uncontrolled pain D. Uncontrolled nausea/vomiting E. Unsure

Evaluation Questions

6. How confident are you in your decision about treatment for your 54 year old patient in the question above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

7. How confident are you in your decision about treatment for your 46 year old patient in the question above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. PARP inhibitors have demonstrated considerable activity in ovarian cancer because of mutations in which of the following genes?

2. A 54-year-old woman with recurrent, BRCA-positive, platinum-sensitive ovarian cancer has recently completed six cycles of paclitaxel/carboplatin with a clinical complete response. Which of the following treatment options would be reasonable for the next phase of her treatment?

3. Which of the following is recommended to be monitored while patients are receiving PARP-inhibitor therapy?

5. For which diagnosis would it be appropriate to consider continuation of PARP inhibitor therapy for a patient admitted through the emergency room on a Friday evening?

Evaluation Questions

6. How confident are you in your decision about treatment for your 54 year old patient in the question above?

7. How confident are you in your decision about treatment for your 46 year old patient in the question above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. PARP inhibitors have demonstrated considerable activity in ovarian cancer because of mutations in which of the following genes?

2. A 54-year-old woman with recurrent, BRCA-positive, platinum-sensitive ovarian cancer has recently completed six cycles of paclitaxel/carboplatin with a clinical complete response. Which of the following treatment options would be reasonable for the next phase of her treatment?

3. Which of the following is recommended to be monitored while patients are receiving PARP-inhibitor therapy?

5. For which diagnosis would it be appropriate to consider continuation of PARP inhibitor therapy for a patient admitted through the emergency room on a Friday evening?

Evaluation Questions

6. How confident are you in your decision about treatment for your 54 year old patient in the question above?

7. How confident are you in your decision about treatment for your 46 year old patient in the question above?

« Return to Activity

Customers who Purchased
this Activity also Purchased